| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1567-5769(01)00073-X |
| P698 | PubMed publication ID | 11515821 |
| P2093 | author name string | C E Hack | |
| G Dickneite | |||
| W K Bleeker | |||
| G M Rigter | |||
| H te Velthuis | |||
| G J van Mierlo | |||
| I G Bos | |||
| P2860 | cites work | A second serine protease associated with mannan-binding lectin that activates complement | Q24311275 |
| Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection | Q33377921 | ||
| A BIOCHEMICAL ABNORMALITY IN HEREDIATRY ANGIONEUROTIC EDEMA: ABSENCE OF SERUM INHIBITOR OF C' 1-ESTERASE. | Q34255146 | ||
| Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serine protease | Q34275196 | ||
| Evaluation of antiviral activity and toxicity of dextran sulfate in feline leukemia virus-infected cats | Q36756157 | ||
| Contribution of Plasma Protease Inhibitors to the Inactivation of Kallikrein in Plasma | Q37007907 | ||
| The inhibition of activated factor XII (hageman factor) by antithrombin III: The effect of other plasma proteinase inhibitors | Q39421556 | ||
| Activation of the first component of complement | Q39509671 | ||
| C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. | Q40684870 | ||
| Inactivation of kallikrein in human plasma | Q40983434 | ||
| Endotoxin-induced pulmonary dysfunction is prevented by C1-esterase inhibitor. | Q41021715 | ||
| Proteolytic inactivation of plasma C1- inhibitor in sepsis | Q41076639 | ||
| C1 inhibitor-C1s complexes are internalized and degraded by the low density lipoprotein receptor-related protein | Q41927379 | ||
| C1 inhibitor-dependent dissociation of human complement component C1 bound to immune complexes | Q41974590 | ||
| Reduction of myocardial infarct size after ischemia and reperfusion by the glycosaminoglycan pentosan polysulfate. | Q47261115 | ||
| Interaction of 125I-labelled complement subcomponents C-1r and C-1s with protease inhibitors in plasma | Q50335850 | ||
| Pharmacokinetic Analysis of Dextran Sulfate in Rats as Pertains to Its Clinical Usefulness for Therapy of HIV Infection | Q52241327 | ||
| C1-esterase inhibitor substitution in sepsis | Q67513455 | ||
| Modulation of contact system proteases by glycosaminoglycans. Selective enhancement of the inhibition of factor XIa | Q71142872 | ||
| The influence of C1-esterase inhibitor substitution on coagulation and cardiorespiratory parameters in an endotoxin-induced rabbit model of hypercoagulability | Q71835944 | ||
| Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway | Q72088344 | ||
| Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion | Q72369137 | ||
| Effects of heparin and N-acetyl heparin on ischemia/reperfusion-induced alterations in myocardial function in the rabbit isolated heart | Q72711318 | ||
| Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion | Q73047646 | ||
| Initiation of contact system activation in plasma is dependent on factor XII autoactivation and not on enhanced susceptibility of factor XII for kallikrein cleavage | Q73851091 | ||
| C1 esterase inhibitor concentrate for capillary leakage syndrome following bone marrow transplantation | Q73877807 | ||
| Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein | Q78975293 | ||
| P433 | issue | 8 | |
| P304 | page(s) | 1583-1595 | |
| P577 | publication date | 2001-08-01 | |
| P1433 | published in | International Immunopharmacology | Q15751306 |
| P1476 | title | The potentiation of human C1-inhibitor by dextran sulphate is transient in vivo: studies in a rat model | |
| P478 | volume | 1 |
| Q40615143 | Complete sequencing and expression of three complement components, C1r, C4 and C1 inhibitor, of the classical activation pathway of the complement system in rainbow trout Oncorhynchus mykiss |
| Q45813756 | Control of IBMIR Induced by Fresh and Cryopreserved Hepatocytes by Low Molecular Weight Dextran Sulfate Versus Heparin |
| Q40484335 | Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond |
| Q28577389 | Inhibition of classical complement activation attenuates liver ischaemia and reperfusion injury in a rat model |
| Q48469178 | Measurement by ELISA of complement factor 4 (C4) in the rat brain: necessity for removal of cerebrovascular proteins |
| Q58143875 | Meconium Is a Potent Activator of Complement in Human Serum and in Piglets |
| Q41821623 | Nebulized C1-Esterase Inhibitor does not Reduce Pulmonary Complement Activation in Rats with Severe Streptococcus Pneumoniae Pneumonia. |
| Q28581087 | Rat C-reactive protein activates the autologous complement system |
| Q73418337 | Recombinant human C1-inhibitor produced in Pichia pastoris has the same inhibitory capacity as plasma C1-inhibitor |
| Q38354158 | The functional integrity of the serpin domain of C1-inhibitor depends on the unique N-terminal domain, as revealed by a pathological mutant. |
Search more.